Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LSTA | 8-K | mixed | 6/10 | Lisata Therapeutics amended its merger agreement with Kuva Labs, reducing the upfront cash consideration from $5.00 to $ | May 29, 2026 |
| SYRE | 8-K | neutral | 3/10 | Spyre Therapeutics held its 2026 Annual Meeting on May 27, 2026, where stockholders approved the amended and restated 20 | May 29, 2026 |
| GNMSF | 6-K | neutral | 2/10 | This 6-K filing reports a routine insider sale by Board member Michael Kavanagh, who sold 526 shares at DKK 1,734.75 eac | May 29, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and two other insiders executed a series of transactions over a 7-day window, including open-marke | May 29, 2026 |
| BFRGW | S-1 | bearish | 5/10 | BullFrog AI Holdings filed an S-1 registration statement to register up to 2,000,000 additional shares of common stock f | May 29, 2026 |
| CTOR | S-3 | bearish | 7/10 | Citius Oncology filed an S-3 registration statement to register 32,931,482 shares of common stock for resale by selling | May 29, 2026 |
| OTLK | 8-K | bearish | 6/10 | Outlook Therapeutics filed an 8-K disclosing a registered direct offering of 8,539,709 shares of common stock to GMS Ven | May 29, 2026 |
| EXEL | CLUSTER | neutral | 3/10 | Two EVPs at Exelixis sold a combined $3.79M in open-market sales over a week, with no insider buying. The sales are mode | May 29, 2026 |
| RXRX | PRESS-RELEASE | neutral | 2/10 | Recursion Pharmaceuticals granted inducement RSU awards covering ~2.99 million shares to 33 new employees under its 2024 | May 29, 2026 |
| ADTX | 8-K | bearish | 8/10 | Aditxt received a Nasdaq delisting notice on May 27, 2026 for failing the minimum stockholders' equity requirement ($2.5 | May 29, 2026 |
| ETON | CLUSTER | bearish | 5/10 | Eton Pharmaceuticals CEO Sean Brynjelsen sold $3.82M worth of stock and CBO David Krempa sold $1.80M (including derivati | May 29, 2026 |
| WHWK | S-3 | bearish | 6/10 | Whitehawk Therapeutics filed an S-3 registration statement to register 22,321,887 shares for resale by selling stockhold | May 29, 2026 |
| ANRO | 3 | neutral | 2/10 | Andrew Miller, Ph.D. filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero securities be | May 29, 2026 |
| LYB | 8-K | neutral | 3/10 | LyondellBasell amended its accounts receivable securitization facility, extending the maturity to June 25, 2027 and redu | May 29, 2026 |
| EDSA | 8-K | neutral | 3/10 | Edesa Biotech held its 2026 Annual Meeting on May 27, 2026, with ~55% of shares represented. Shareholders approved all p | May 29, 2026 |
| ANAB | 8-K | neutral | 2/10 | AnaptysBio filed an 8-K under Item 7.01 to disclose that it has filed Form 8937 with the IRS regarding the tax treatment | May 29, 2026 |
| ENVB | 8-K | bearish | 6/10 | Enveric Biosciences filed an 8-K reporting two routine items: (1) the Compensation Committee approved new forms of RSU a | May 29, 2026 |
| EXEL | 8-K | neutral | 3/10 | Exelixis held its 2026 Annual Meeting on May 26, 2026, where stockholders approved the amendment and restatement of the | May 29, 2026 |
| CLYM | S-3 | neutral | 4/10 | Climb Bio filed an S-3 registration statement to register 11,587,000 shares of common stock for resale by selling stockh | May 29, 2026 |
| VREOF | 8-K | mixed | 6/10 | Vireo Growth exercised its purchase option to acquire a 389,000 sq ft cannabis cultivation facility in Perth, NY from an | May 29, 2026 |
| AWHL | CLUSTER | bullish | 5/10 | Two directors at Aspira Women's Health purchased a total of $32K in shares on the same day at $0.45/share, three days af | May 29, 2026 |
| JAZZ | 8-K | neutral | 2/10 | Director Anne O'Riordan informed Jazz Pharmaceuticals' board that she will not stand for re-election at the 2026 annual | May 29, 2026 |
| VACHW | 8-K | neutral | 5/10 | Voyager Acquisition Corp. (SPAC) entered into a securities purchase agreement to issue $27.5M aggregate principal of sen | May 29, 2026 |
| OCS | PRESS-RELEASE | bearish | 7/10 | Oculis announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edema (DME) failed to me | May 29, 2026 |
| CTTH | S-1/A | bearish | 6/10 | CTT Pharmaceutical Holdings, Inc. filed Amendment No. 2 to its S-1 registration statement, registering 6,250,000 shares | May 29, 2026 |
| EPRX | 6-K | neutral | 3/10 | Eupraxia Pharmaceuticals filed its management information circular and proxy materials for the upcoming annual general m | May 29, 2026 |
| EPRX | 6-K | neutral | 2/10 | Eupraxia Pharmaceuticals filed a 6-K confirming that proxy-related materials for its upcoming shareholder meeting were m | May 29, 2026 |
| MNKD | PRESS-RELEASE | bullish | 8/10 | MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient po | May 29, 2026 |
| USNA | CLUSTER | neutral | 2/10 | Three USNA insiders (CFO, Chief People Officer, Director) collectively sold $250K in open-market shares over a one-week | May 29, 2026 |
| OPTH | 6-K | bullish | 6/10 | Optimi Health Corp. acknowledged final TGA recommendations expanding the Authorized Prescriber scheme for psilocybin and | May 29, 2026 |